Anthony Mancini, Chief Global Commercialization Officer of Revolution Medicines, Inc. (NASDAQ:RVMD), filed a Form 4 on September 18, 2026, disclosing the sale of common stock on September 16, 2026 pursuant to a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Reporting person: Anthony Mancini, Chief Global Commercialization Officer of Revolution Medicines, Inc.
  • First sale: 27 shares of common stock disposed of at a weighted average price of $195.0521 per share on September 16, 2026.
  • Second sale: 1,747 shares of common stock disposed of at $199.3032 per share on September 16, 2026.
  • Remaining beneficial ownership: 42,116 shares of common stock held directly following the reported transactions, including 39,575 restricted stock units.
  • Plan basis: Both sales were made pursuant to a Rule 10b5-1 instruction letter adopted on June 15, 2026 to satisfy tax withholding obligations upon the vesting of restricted stock units.
  • Price range: The 27-share transaction was executed in multiple trades at prices ranging from $195.03 to $195.07, inclusive, with the weighted average reported in the filing.

Mancini Disposes of Revolution Medicines Shares for Tax Withholding

According to the filing, Anthony Mancini, serving as Chief Global Commercialization Officer of Revolution Medicines, Inc., sold a total of 1,774 shares of common stock on September 16, 2026. The transactions were executed under a Rule 10b5-1 instruction letter that Mancini adopted on June 15, 2026, specifically to satisfy his tax withholding obligation upon the vesting of restricted stock units, as disclosed in the filing's footnotes.

The first transaction involved 27 shares disposed of at a weighted average sale price of $195.0521 per share. The filing notes that this transaction was executed across multiple trades at prices ranging from $195.03 to $195.07, inclusive, and that full information regarding the number of shares sold at each price within that range is available upon request. The second transaction covered 1,747 shares at $199.3032 per share. Following both sales, Mancini directly held 42,116 shares of common stock, of which 39,575 are restricted stock units, according to the filing.

The Form 4 was signed by Jack Anders as attorney-in-fact for Anthony Mancini and filed on September 18, 2026. The filing indicates that the transactions were conducted under the affirmative defense conditions of Rule 10b5-1(c), with the checkbox on the form confirming the plan designation.

What Was Disclosed

The filing disclosed two open-market sales of Revolution Medicines common stock by Chief Global Commercialization Officer Anthony Mancini on September 16, 2026, totaling 1,774 shares sold under a pre-established 10b5-1 plan for tax withholding purposes, leaving him with 42,116 shares beneficially owned directly.